Inhibition of Proprotein Convertase Ski-1 Blocks Transcription of Key Extracellular Matrix Genes Regulating Osteoblastic Mineralization by Gorski, Jeff P. et al.
Boise State University
ScholarWorks
Biomolecular Research Center Publications and
Presentations Biomolecular Research Center
1-21-2011
Inhibition of Proprotein Convertase Ski-1 Blocks
Transcription of Key Extracellular Matrix Genes
Regulating Osteoblastic Mineralization
Jeff P. Gorski
University of Missouri
Nichole T. Huffman
University of Missouri
Sridar Chittur
University at Albany
Ronald J. Midura
Lerner Institute
Claudine Black
University of Missouri
See next page for additional authors
This is an author-produced, peer-reviewed version of this article. The final, definitive version of this document can be found online at Journal of
Biological Chemistry, published by American Society for Biochemistry and Molecular Biology. Copyright restrictions may apply. DOI: 10.1074/
jbc.M110.151647
Authors
Jeff P. Gorski, Nichole T. Huffman, Sridar Chittur, Ronald J. Midura, Claudine Black, Julia Oxford, and Nabil
G. Seidah
This article is available at ScholarWorks: http://scholarworks.boisestate.edu/brc_facpubs/5
 This is an author-produced, peer-reviewed version of this article.  The final, definitive version of this document can be found online at Journal of 
Biological Chemistry, published by American Society for Biochemistry and Molecular Biology. Copyright restrictions may apply.  DOI: 
10.1074/jbc.M110.151647 
 
INHIBITION OF PROPROTEIN CONVERTASE SKI-1 BLOCKS TRANSCRIPTION 
OF KEY EXTRACELLULAR MATRIX GENES REGULATING OSTEOBLASTIC 
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      Mineralization, a characteristic phenotypic 
property of osteoblastic lineage cells, was 
blocked by AEBSF and dec-RRLL-cmk, 
inhibitors of SKI-1 (site 1; subtilisin kexin like-
1) protease. Since SKI-1 is required for 
activation of SREBP and CREB/ATF family 
transcription factors, we tested the effect of 
these inhibitors on gene expression. AEBSF 
decreased expression of 140 genes by 1.5- to 3.0-
fold including Phex, Dmp1, COL1A1, COL11A1 
and fibronectin. Direct comparison of AEBSF 
and dec-RRLL-cmk, a more specific SKI-1 
inhibitor,  demonstrated that expression of 
Phex, Dmp1, COL11A1 and fibronectin was 
reduced by both while COL1A2 and HMGCS1 
were reduced only by AEBSF. AEBSF and dec-
RRLL-cmk decreased the nuclear content of 
SKI-1 activated forms of transcription factors 
SREBP-1, SREBP-2, and OASIS.  In contrast 
to AEBSF, the actions of dec-RRLL-cmk 
represent the sum of its direct actions on SKI-1 
and indirect actions on caspase-3.  Specifically, 
dec-RRLL-cmk reduced intracellular caspase-3 
activity by blocking the formation of activated 
19 kDa caspase-3.  Conversely, over-expression 
of SKI-1 activated SREBP-1a and CREB-H in 
UMR106-01 osteoblastic cells increased the 
number of mineralized foci and altered their 
morphology to yield mineralization nodules, 
respectively.  In summary, SKI-1  regulates the 
activation of transmembrane transcription 
factor precursors required for expression of 
key genes required for mineralization of 
osteoblastic cultures in vitro and bone 
formation in vivo.  Our results indicate that the 
differentiated phenotype of osteoblastic cells, 
and possibly osteocytes, depends upon the non-
apoptotic actions of SKI-1.  
     Bone formation and mineralization is a multi-
step process of differentiated osteoblastic cells.  
Based upon an analysis of gene expression during 
osteogenesis, Lian and Stein (1) noted that ―peak 
levels of expressed genes reflect a developmental 
sequence of bone cell differentiation characterized 
by three principal periods: proliferation, 
extracellular matrix maturation and mineralization, 
and two restriction points to which the cells can 
progress but cannot pass without further signals.‖   
These authors defined these three periods of 
osteoblastic differentiation in terms of patterns of 
sequential gene expression.  For example, 
fibronectin and type I collagen expression denoted 
the pattern of pre-osteoblastic cells, alkaline 
phosphatase and MGP
6
 reflected the matrix 
maturation stage, and, osteopontin and osteocalcin 
reflected the mineralization stage of mature 
osteoblastic cells (1).  However, the number of 
genes required for normal bone formation and 
mineralization has grown rapidly to include Phex 
(Phex), dentin matrix protein1 (Dmp1), and type 
XI collagen (COL11).    
     Phex (phosphate regulating endopeptidase 
homolog, X-linked) is a transmembrane 
metalloendoprotease enriched on bone osteoblasts 
and osteocytes (2).  It is essential for phosphate 
homeostasis and bone mineralization since loss of 
function mutations result in X-linked 
hypophosphatemic rickets (3).  Acidic 
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phosphorylated dentin matrix protein 1 is highly 
expressed in teeth and osteocytes in bone. 
Mutations in Dmp1 cause autosomal recessive 
hypophosphatemic rickets (4, 5). Elevated 
circulating levels of fibroblast growth factor 23 are 
a characteristic shared by both this human 
condition and by mice lacking Dmp1 (5).  The 
hypophosphatemic rickets and elevated FGF23 
levels that occur in Dmp1 null mice resemble the 
‗hyp‘ mouse, which has an inactivating mutation 
in Phex.  Since skeletal abnormalities in both these 
animal models can be largely but not completely 
rescued by feeding a high phosphate diet,  DMP1 
and Phex regulate an essential pathway controlling 
serum phosphate levels needed for mineralization 
of teeth and bone.  Type XI collagen regulates the 
rate of fibrillogenesis of type I and II collagen and 
the ultimate size of fibrils (6).  Homozygous cho 
mice containing a frame shift mutation in the 
COL11A1 gene die at birth with severe 
abnormalities of bone and tracheal cartilage
 
(7).  In 
humans, COL11A1 mutations cause Marshall and 
Stickler syndromes (8) characterized by 
craniofacial abnormalities, nearsightedness and 
hearing deficiencies.  Finally, fibronectin is a 
multi-functional matrix organizing protein 
possessing binding sites for collagen, 
glycosaminoglycan chains, and cell adhesion 
receptors. Blocking antibodies against the 
fibronectin receptor inhibit the mineralization of 
osteoblastic cells in culture (9-11).  Although 
genetic knockouts and mutations causing skeletal 
abnormalities have identified these and other 
genes, detailed mechanisms controlling bone 
formation and mineralization are incompletely 
understood. 
We have used osteoblastic culture models to 
investigate the mechanism controlling bone 
mineralization (12-18).   Mineralization occurs 
within spherical, macromolecular, extracellular, 
vesicle-enriched complexes termed 
biomineralization foci.  Since BMF 
phosphoprotein biomarkers can be used to define 
areas of growing periosteum and developing 
fracture callus prior to their mineralization
 
(14, 
15), osteoblastic cultures appear to model bone 
formation in vivo.  Proteomic analyses on laser 
micro dissected mineralized BMF show they are 
enriched in phosphoproteins BSP and BAG-75 and 
their fragments.  Interestingly, both 
phosphoprotein cleavage and mineralization of 
BMF can be completely blocked with covalent 
serine protease inhibitor AEBSF, whereas 15 other 
inhibitors against acidic, metallo-, and sulfhydryl 
proteases were without effect (16).  Based on these 
results, we hypothesized that initiation of bone 
mineralization is controlled by a serine protease.  
We recently showed that BMF contained an 
active, 105 kDa form of SKI-1 protease (18).  
SKI-1 is a member of the proprotein 
convertase family (19).  PCs, serine proteases 
related to bacterial subtilisin and yeast kexin, 
cleave and activate growth factors, neuropeptides, 
toxins, glycoproteins, viral capsid proteins, and 
transcription factors.  Transmembrane 
transcription factor precursors SREBP-1 and -2 are 
activated in a sequential process involving first 
SKI-1 cleavage and then S2P protease cleavage 
(20).  SREBPs can also be activated by caspase-3 
(21, 22).  The N-terminal fragments of SREBP-1 
and SREBP-2 can then be imported into the 
nucleus where each regulates gene expression by 
binding to promoters containing consensus SRE 
sequences (23).  Members of the CREB/ATF 
family of transcription factors [ATF-6, LUMAN 
(CREB3), OASIS/BBF2H7 (CREB3L2), CREB-
H, CREB-4, and AIbZIP/Tisp40 (CREB3L4)] also 
require SKI-1 catalyzed activation.  By activating 
ATF-6, SKI-1 serves as an initiator of the 
unfolded protein response which decreases cellular 
stress by increasing chaperone production, 
influencing ER-associated degradation of proteins, 
and regulating membrane remodeling (24).  
Recent studies indicate that SKI-1 is required 
for normal bone formation.  First, the skeletons of 
mice deficient in OASIS (25) exhibit a severe 
osteopenia characterized by a type I collagen-
deficient bone matrix and reduced osteoblastic 
activity (26). Second, mice over-expressing ICER, 
a dominant negative effector of CREB/ATF 
transcription factors, displayed dramatically 
reduced trabecular bone and a reduced femoral 
bone formation rate (27).  Third, SKI-1 is required 
for normal cartilage morphogenesis in zebrafish 
(28).  Finally, conditional inactivation of SKI-1 in 
mice using a type II collagen Cre recombinase 
transgene leads to abnormal growth plate 
calcification (29).  
The purpose of this study was to determine 
whether SKI-1 protease controls initiation of 
osteoblastic mineralization.   
 
EXPERIMENTAL PROCEDURES 
Growth, mineralization and treatment of UMR 
cells with protease inhibitors.  UMR 106-01 BSP 
cells were passaged and cultured as described 
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previously (12). Cells were seeded at a density of 
1.0 x 10
5 
cells/cm
2
 in Growth Medium.  After 24 
h, Growth Medium containing 0.5% BSA 
(Millipore #82-045-1) was exchanged for FBS 
containing medium.  Sixty-four hours after plating, 
spent medium was exchanged with Mineralization 
Media (Growth Medium containing 0.1% BSA 
and 6.5 mM BGP). Addition of a supplemental 
phosphate source to UMR 106-01 cultures prior to 
64 h had no effect on the formation of mineral 
crystals (Midura and Gorski, manuscript in 
preparation).  Cultures were then incubated for up 
to an additional 24 h at which time they were fixed 
with 70% ethanol. 
In some experiments, serine protease inhibitor 
AEBSF (EMD Biosciences, Inc.) or dec-RRLL-
cmk (Bachem, Inc.) was added over a range of 
concentrations in Mineralization Media at 64 h 
after plating.  We have shown previously (16) that 
100 µM AEBSF is the minimum dosage able to 
effectively block mineralization of BMF within 
serum-depleted UMR cultures.   
The extent of mineralization was either 
assessed visually by fluorescence microscopy 
(after staining with 10 µg/ml Alizarin red S dye) 
or quantitated by colorimetric calcium assay (17) 
by reference to a standard curve.  In the latter case, 
calcium was first extracted from culture wells with 
acidified 70% ethanol and the extracts were then 
concentrated prior to analysis.  
Transgenic DMP1 GFP mice were kindly 
provided by Drs. I. Kalajzic and D.W. Rowe, 
University of Connecticut Health Center.   
SDS gel electrophoresis and Western blotting.  
Protein samples were electrophoresed under 
reducing conditions on 4-20% linear gradient gels 
(Pierce Chem. /Thermo Scientific) according to 
Laemmli (30) and electro blotted onto PVDF 
membranes (Millipore Corp.) for 1.5-2 h at 100 
volts in 10 mM CAPS buffer (pH 11.0) containing 
10% methanol.  Blots were processed with 
primary antibody and horseradish peroxidase-
conjugated secondary antibody as described 
previously (17) and chemiluminescent digital 
images captured with a Fuji LAS-4000.     
Anti-SKI-1 antibodies [h-SKI-CT (C-terminal 
specific for aa 1036-1051); 723.03 (recognizes 
pro-SKI-1); 705.02 (recognizes residues 634-651)] 
[see Pullikotil et al. (31, 32) for details] and anti-
CREB-H antibodies (33) were a gift from Dr. K 
Zhang, Wayne State Univ.  Antibodies against 
SREBP-1 (aa 38-89), SREBP-2 (aa 424-473), and 
GAPDH were purchased from Sigma Chemical 
Inc. while antibodies against OASIS were 
obtained from Aviva Systems Biology.    
Isolation of nuclear and cytoplasmic fractions  
from UMR 106-01 cultures.  UMR 106-01 cells 
were cultured under serum depleted conditions as 
described above.    Sixty-four hours after plating, 
the medium was exchanged for Mineralization 
Medium (18); some of the cultures were also 
treated with 100 µM AEBSF, 40 µM dec-RRLL-
cmk, 10 µM Z-DEVD-fmk or 20 µM Z-DEVD-
fmk. Cultures were then incubated for an 
additional 12 hours and then the nuclear and 
cytoplasmic fractions were prepared using a 
Thermo Scientific NE-PER Nuclear and 
Cytoplasmic Extraction kit per the manufacturer‘s 
instructions. Extracts were aliquoted and stored at 
-80°C until subjected to Western blotting. 
Transfection with plasmids.  UMR 106-01 cells 
were plated in 24 well plates with Growth Medium 
containing 10% FBS. At 40 h after plating, 
transfections were carried out in Growth Medium 
containing 1% FBS.  Initially, each plasmid was 
pre-titered to determine an optimum dosage; cell 
cultures were transfected with 0.25-0.75 µg of 
plasmid DNA at three different levels of 
Metafectene Pro transfection reagent (Biontex) per 
manufacturer‘s protocol.  Individual plasmids and 
Metafectene Pro reagent were pre-incubated at 
room temperature for 20 minutes prior to addition 
to cells for 24 hrs at which time the mixture was 
exchanged for serum-free Mineralization Medium 
containing 0.1% BSA.   An optimized dosage of 
plasmid was used in subsequent studies examining 
the effect of over-expression of recombinant 
transcription factors on mineralization.  At 88 hrs 
after plating, cultures were fixed in 70% ethanol 
and then stained with 10 µg/ml Alizarin red S dye. 
Both bright field and fluorescence microscopic 
images were obtained.  Alternatively, calcium was 
quantitated with a colorimetric assay (16). 
Expression plasmids were prepared as follows.  
cDNAs coding for hSREBP-1a, -1c and -2 were 
purchased from Origene. PCR was used to clone 
their N-terminal fragments and to then tag them 
with the V5 epitope (GKPIPNPLLGLDST) at 
their C-terminus.  The resultant plasmids produced 
the following proteins:  hSREBP1a = aa 1-511-
V5; SREBP-1c = aa 55-511-V5; and, SREBP-2 = 
aa 1-475-V5.   [Expression plasmids OASIS 
TMC-HA tag, OASIS TMC, and CREB-H TMC 
were kindly provided by Dr. P. O`Hare (Marie 
Curie Research Institute, United Kingdom)]. 
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Extraction of proteins from UMR 106-01 cultures.  
UMR 106-01 cells were seeded in 48-well plates 
and grown in serum depleted conditions as 
described previously (16, 17).  During the final 24 
h mineralization period, wells were exchanged 
with Mineralization Medium containing 0.1% 
BSA; some of the wells also received 100 µM 
AEBSF or 40 µM dec-RRLL-cmk.  At the 
conclusion of the culture period, media was 
removed, inactivated at 95°C for 5 min, dialyzed 
against 5% acetic acid, and lyophilized to dryness. 
The cell layer was extracted as previously 
described (16); EDTA extracts were immediately 
inactivated at 95 and processed as described 
above.   Subsequent Urea/CHAPS cell layer 
extracts (16) were homogenized and then 
ultracentrifuged at 30,000 rpm (~100,000 x g) for 
1 h in an SW50.1 rotor prior to SDS PAGE and 
Western blotting studies. 
Laser micro dissection of BMF.  UMR 106-01 
cells were plated onto glass slides, mineralized, 
and processed for laser micro dissection, 
extraction and Western blotting as described by 
Huffman et al. (16).   
Primary calvarial cell isolation and cell culture.  
Primary mouse osteoblasts were isolated from 
calvaria of 5- to 7-day-old transgenic DMP1 GFP 
mice (34) using a modification of a published 
method (35, 36).  Briefly, four sequential 20-min 
digests were performed in Hanks' balanced salt 
solution containing 0.05% trypsin and 0.2% 
collagenase. Fractions 2 to 4 were pooled, 
centrifuged, and re-suspended in α-MEM medium 
containing 10% FBS, 2 mM L-glutamine, 100 
units/ml penicillin, and 30 μg/ml gentamicin (α-
Growth Medium).  2 × 10
6
 cells were plated per T-
75-cm
2
 flask and allowed to reach confluency. 
Flasks were then trypsinized and the cells plated 
onto 48-well culture dishes.  At confluency, the 
media was changed to α-MEM containing 5% 
FBS, 50 μg/ml ascorbic acid, 5 mM beta-
glycerolphosphate, and antibiotics.  BGP was 
omitted from wells that served as un-mineralized 
controls.  
Some cultures were treated on days 6 and 9 
with 8 μM dec-RRLL-cmk or 10 µM AEBSF.  On 
day 12, cultures were either incubated with MTT 
or were fixed with 2% p-formaldehyde and 
processed for Alizarin red S staining.  Images 
were taken with a Nikon T2000 fluorescence 
microscope equipped with a CCD camera.    
DNA array.  Triplicate UMR 106-01 cultures were 
plated (13, 16) and grown with or without 400 µM 
AEBSF for 12 h prior to isolation of total RNA 
(~5 g) and then converted to single stranded 
cDNA using Superscript II reverse transcriptase 
(InVitrogen, Inc.) and the Gene Chip T7 promoter 
primer kit.  [Note:  the minimum effective dose of 
AEBSF capable of completely blocking 
mineralization in UMR 106-01 cultures is 100 µM 
in serum free media and 400 µM in media 
containing 10% FBS (16)].  Single stranded cDNA 
was then converted to double stranded cDNA 
using DNA polymerase I DNA ligase and RNase 
H from E. coli. The double stranded cDNA was 
purified using a cleanup kit from Affymetrix and 
converted to biotinylated cRNA by in vitro 
transcription using T7 polymerase and biotinylated 
ribonucleotides (Affymetrix). This was 
subsequently fragmented by metal induced 
hydrolysis to yield 35-200 base fragments that 
were hybridized to the Affymetrix Rat Genome 
230 Plus 2.0 oligonucleotide arrays. After 
hybridization, the chip was washed and stained 
with streptavidin-phycoerythrin before being 
scanned. An antibody amplification staining 
protocol that used biotinylated goat IgG followed 
by a second SAPE staining increased the 
sensitivity of the assay. The chip was then scanned 
and images analyzed qualitatively using 
Affymetrix Gene Chip Operating System 
Software. 
Microarray data analysis. CEL data files were 
imported into Gene Spring GX software (v10) and 
the data was normalized using either the MAS5 or 
the GCRMA algorithm. The gene list was filtered 
to exclude those which showed low signal values 
across all samples (i.e. bottom 20th percentile). 
Selection of statistically significant genes from 
each expression profile was done using an 
unpaired t-test with a p-value cut off of < 0.05.  
The multiple testing correction (Benjamini and 
Hochberg false discovery rate, p-value <0.05) was 
integrated within each test. Differential expression 
was defined as ≥1.5-fold change in expression 
found using both MAS5 and GCRMA analysis. 
Using this stringent criteria avoids false positives 
associated with use of MAS5 alone as well as well 
as facilitates the ability of GCRMA to account for 
non-specific hybridization related background 
signal.      
Isolation of RNA from serum depleted osteoblastic 
cultures and conversion to cDNA.  UMR 106-01 
cells were plated and grown under serum depleted 
conditions (13, 16).  At 64 h after plating, the 
media was exchanged with serum-free 
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Mineralization Media.  At 76 h after plating, 
media was removed from each well and cells were 
quickly lysed with STAT-60 (Tel-Test, Inc.); the 
lysates were then immediately frozen and stored in 
liquid nitrogen vapor.  Total RNA was isolated 
according to manufacturer's instructions (Tel-Test, 
Inc.).  Each RNA pellet was washed 2 times with 
80% ethanol and then air dried prior to re-
suspending in 10 µl RNase-free water containing 
4% RNAsin inhibitor (Promega, Inc.).    cDNA 
was produced using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) 
and stored frozen in aliquots. 
       For real time PCR, cDNA preparations were 
diluted and added to 96-well plates containing 
Taqman Master Mix solution and either the 
appropriate FAM-(6-carboxyfluorescein)-labeled 
expression gene primer set or the VIC-labeled -
actin control primer set (ABI, Inc.).  Plates were 
run on an ABI 7000 Real Time system using pre-
programmed software.   All calculations were 
made by the Delta-Delta CT method by 
comparison to the -actin control.  
Assay of Caspase-3.  Recombinant caspase-3 
(Sigma Chem. Co.) and lysates of UMR106-01 
cultures were assayed using a fluorescent substrate 
and reagents from Ana-Spec, Inc. (#71118) 
according to the manufacturer‘s protocol. 
Assay of SKI-1 Peptidase Activity.  UMR106-01 
cultures were cultured as usual in 48-well plates 
and treated with inhibitors as described above.  
The media was exchanged for serum-free medium 
and then the total cell layer was disrupted by 
scraping into reaction buffer and aliquots were 
immediately assayed using a succinylated 
TISRRLL-MCA substrate (37) and a fluorescent 
plate reader at 0, 0.5, 1, and 2 h. Rates were 
extrapolated from kinetic reaction curves.         
 
RESULTS  
Activated 105 kDa form of SKI-1 is present in 
biomineralization foci.  SKI-1 protease is 
synthesized as a membrane bound precursor of 
145 kDa (38) and is activated by autolytic 
cleavage to generate catalytically active 105 kDa 
(membrane bound) and 98 kDa (shed) forms (38, 
39).   SKI-1 can be inactivated by the irreversible 
covalent serine protease inhibitor AEBSF.   Since 
we showed previously that AEBSF blocked 
mineralization and inhibited fragmentation of 
BMF biomarkers BSP and BAG-75 (16), we asked 
if active SKI-1 is associated with extracellular 
biomineralization foci and whether AEBSF alters 
the distribution of SKI-1 within mineralizing 
cultures.    
Mineralized BMF were isolated by laser micro  
dissection from UMR 106-01 cultures and  
Western blotted with a polyclonal antibody 
recognizing the C-terminal cytosolic tail of SKI-1 
(32).  Only the 105 kDa form was present in BMF 
isolated from mineralized cultures (lane BMF, Fig. 
1A).  In contrast, the CL-Min and CL-UnMin 
lanes contained the 105 kDa band along with 
presumed fragments at 70 and 50 kDa (Fig. 1A).  
However, the 70 and 50 kDa components were not 
detected in micro dissected BMF.  While the BMF 
fraction contains only mineralized foci (Fig. 1) 
(16), CL-Min and CL-UnMin fractions represent 
extracts of the cell layer from mineralized and un-
mineralized cultures, respectively, which includes 
cells and BMF.  
Cell layers were extracted with a two step 
protocol devised to efficiently extract proteins 
from cells and the extracellular matrix.  Mild 
EDTA extraction predominantly removes 
materials associated with extracellular BMF 
complexes, whereas extraction with 8M 
urea/CHAPS recovers residual intracellular and 
extracellular matrix components (16).  Activated 
105 kDa SKI-1 was present in the EDTA extract 
but absent from AEBSF-treated or un-mineralized 
cultures (Fig. 1B) suggesting transport of SKI-1 to 
extracellular BMF occurs only during 
mineralization.  Urea/CHAPS extracts contained 
similar amounts of 105 kDa SKI-1 regardless of 
the culture condition.  The culture media contained 
145 kDa SKI-1 precursor and a 50 kDa fragment 
band.  Due to the specificity of the antibody and 
the structure of SKI-1 (31, 32, 38, 39), we assume 
that all forms detected (145, 105, 70, and 50 kDa) 
contain the transmembrane sequence and are 
associated with membranes or vesicles released 
from cells.  Interestingly, the amount of 50 kDa 
band in the media was found to be lower in 
mineralized cultures indicating that breakdown of 
SKI-1 may be increased under non-mineralizing 
conditions (Fig. 1B).      
Treatment of osteoblastic cultures with a specific 
SKI-1 inhibitor also blocks mineralization.  The 
structure of dec-RRLL-cmk is based on the 
preferred substrate specificity of SKI-1 and is 
more specific than AEBSF (32, 37, 38).  When 
UMR106-01 cells were treated with dec-RRLL-
cmk, mineralization was progressively blocked as 
the concentration of inhibitor was increased (Fig. 
2A).  Forty micromolar dec-RRLL-cmk represents 
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a minimum effective inhibitory dose compared 
with 100 µM AEBSF (Fig. 2A and B) (16).  By 
contrast, a structurally similar furin inhibitor (40),  
dec-RVKR-cmk, was without effect (Fig. 2C).   
Importantly, assays of treated cultures also 
demonstrated that AEBSF and dec-RRLL-cmk 
significantly decreased SKI-1 peptidase activity by 
about 30 and 40%, respectively, while treatment 
with other inhibitors containing analogous reactive 
functional groups were without a negative effect 
(Table 1).  AEBSF and dec-RRLL-cmk do not 
significantly decrease cell number (Fig 1) (16), 
while Z-DEVD-OPH and dec-RVKR-cmk reduce 
cell viability by no more than 15% (not shown).       
We also treated primary calvarial osteoblastic 
cultures from transgenic DMP1-GFP mice (34-36) 
with dec-RRLL-cmk.  Since GFP expression 
precedes mineralization in these cultures, this 
protein serves as a marker of where and when 
mineralization will occur in these longer term 
cultures.   Osteoblastic precursors were plated onto 
collagen coated wells and grown under 
mineralizing conditions for up to 12 days in the 
presence of either 0, 1, or 8 µM dec-RRLL-cmk.  
Concentrations of AEBSF and dec-RRLL-cmk 
were lowered to accommodate the longer exposure 
with primary cells versus UMR 106-01 cells.  
Mineral crystals were detected by staining with 
Alizarin red S and correlated with GFP expression.  
Focal areas of GFP-positive cells generally 
appeared about 6-8 days after plating and go on to 
form mineralized nodules by about day 12 (Fig. 
3A). Exposure to 8 µM dec-RRLL-cmk inhibitor 
diminished expression of the DMP1-GFP reporter 
(Fig. 3B), as well as blocking mineralization.   As 
a positive control, 10 µM AEBSF also completely 
blocked mineralization and DMP1-GFP reporter 
expression by primary calvarial cultures (16) (Fig. 
3C).  These results indicate that SKI-1 is required 
for progression through the osteoblastic 
mineralization stage and the transition to the 
embedded osteoblast or osteocyte stage.   
Short-term treatment of osteoblastic cells with 
AEBSF decreases transcription of mineralization-
related genes.  Since SKI-1 and S2P catalyze the 
release of activated transcription factors from the 
cis/medial Golgi (19), we asked whether AEBSF 
blocks transcription of mineralization related 
genes.  UMR106-01 cultures were treated for 12 h 
(from 64-76 h after plating)                                                                                                       
with or without a minimum concentration of 
AEBSF sufficient to block mineralization.  
UMR106-01 cultures begin to nucleate calcium 
phosphate crystals within biomineralization foci at 
76 h (16, 17).  Total RNA was isolated, converted 
to cDNA prior to labeling and incubated with 
whole rat genome arrays (see EXPERIMENTAL 
PROCEDURES for details).   
AEBSF treatment reduced expression of 140 
genes by 1.5 to 3-fold while twenty-eight genes 
were found to be increased by at least 1.5-fold 
[Array data has been deposited with the Gene 
Expression Omnibus database (series accession 
number GSE21476)].  It is noteworthy that genes 
encoding a number of mineralization related 
extracellular matrix proteins were reduced (Table 
2), e.g., DMP1, type I procollagen alpha 1 and 
alpha 2 chains, type XI procollagen alpha 1 chain, 
fibronectin, matrilin 3, ectonucleotide 
pyrophosphatase/phosphodiesterase 2 and 3, and 
tenascin-C and -N.  Interestingly, the reduced 
expression for  DMP1 observed (Table 2) is 
consistent with the lack of DMP1-GFP transgene 
expression noted in primary calvarial cultures 
treated with these inhibitors (Fig. 3).    
Dec-RRLL-cmk also blocks transcription of Dmp1, 
Phex, FN1, COL11A1 genes.  Because dec-RRLL-
cmk is a more specific inhibitor of SKI-1 than 
AEBSF (20), we predicted that it should reproduce 
those actions of AEBSF (Table 2) which are 
mediated by SKI-1.  To test this, UMR106-01 
cultures were again treated for 12 h with 40 µM 
dec-RRLL-cmk (Fig. 2).  Parallel cultures were 
also treated with AEBSF (16) (Fig. 2B).  This 
study was carried out under conditions of serum 
deprivation to reduce exposure to cholesterol 
which inhibits SCAP-mediated transport of 
SREBPs towards the cis/medial Golgi where they 
are activated by SKI-1 and S2P (41).  We showed 
earlier that the amount of mineral deposited in 
UMR106-01 cultures is unaffected by serum 
depletion (16).   
Total RNA was isolated and converted to 
cDNA.   Quantitative PCR was then carried out on 
a representative group of genes decreased by 
AEBSF (Table 2).  Expression of HMG-CoA 
synthase (HMGCS1) was also included as a 
positive control since it is regulated by SREBP 
transcription factors activated by SKI-1 (42, 43).  
Other cultures were treated with inhibitors until 88 
h when the amount of mineralization was 
determined.   As expected, both inhibitors blocked 
mineralization by greater than 90% (data not 
shown but similar to that in Figure 2B).    
All qPCR results are plotted in Figure 4 as a 
percentage of the expression in cultures treated 
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with mineralizing conditions.  Visual inspection of 
the data reveals two patterns.  First, expression of 
DMP1, procollagen XI  alpha 1 chain, Phex, and 
fibronectin was significantly decreased by each 
SKI-1 inhibitor (Figs. 4A-D).  For each gene, the 
average knockdown with AEBSF was found to be 
quantitatively greater than that for dec-RRLL-cmk 
(Figs. 4A-D), but differences were not significant.  
In the second pattern, highest expression of COL1 
A2  and HMGCS1 occurred in dec-RRLL-cmk 
treated cultures whereas that for mineralizing 
control or for AEBSF-treated culture was found to 
be significantly lower (Fig. 4E and F).  Expression 
of HMGCS1 in AEBSF treated cells was 
indistinguishable from controls (+BGP, Fig. 4E), 
whereas expression of COL1 A2 was lower in 
AEBSF treated cells than controls (+BGP vs. 
AEBSF, p=0.05, Fig. 4E).  The qPCR results with 
AEBSF are very similar to array results for DMP1, 
procollagen XI  alpha 1 chain, Phex, fibronectin, 
and COL1 A2 (Table 2).  The results for HMGCS1 
were unexpected since its expression is tightly 
regulated by SREBP-1 and SREBP-2 (42, 43) and 
thus should be dependent upon SKI-1.   Based on 
qPCR results, mineralization in UMR106-01 
cultures correlates most closely with the 
expression of DMP1, COL11 A1, fibronectin, and 
Phex (compare Figs. 2 and 4).   
Activation of caspase-3 is regulated differently in 
AEBSF and dec-RRLL-cmk treated cultures.  As 
first shown by Wang et al. (20, 21), activation of 
SREBP-1 and SREBP-2 can be also mediated by 
caspase-3.  Caspase-3 and SKI-1 cleave these 
factors at different sites producing different sized, 
transcriptionally active N-terminal fragments (21, 
22).  We therefore tested whether a caspase-3/-7 
specific inhibitor would also inhibit mineralization 
of BMF.  Interestingly, 10 and 20 µM Z-DEVD-
fmk had no significant effect on mineralization in 
UMR06-01 cultures (Fig. 5A).  By comparison, 
100 µM AEBSF and 50 µM dec-RRLL-cmk 
blocked mineralization by >85% (Fig. 5A).   
       To determine if caspase-3 was specifically 
inactivated by Z-DEVD-fmk, the cytosolic 
fraction of cell lysates was assayed using a small 
fluorescent peptide substrate.  Caspase-7 is 
predominantly membrane bound (44)  under these 
conditions and should have been removed by 
centrifugation prior to assays.   Intracellular 
caspase-3 catalytic activity was blocked by up to 
80%  by Z-DEVD-fmk and was also reduced 
about 60% by dec-RRLL-cmk (Fig. 5B).  
However, AEBSF had no effect.  To establish if 
dec-RRLL-cmk directly inactivated caspase-3, we 
incubated recombinant caspase-3 with various 
inhibitors for 30 min and then measured its 
catalytic function.  As shown in Figure 5C, 50 µM 
dec-RRLL-cmk and 100 µM AEBSF were all 
without effect—suggesting that the former acts 
indirectly to block procaspase-3 activation.   
In view of the differential gene expression 
patterns observed with AEBSF and dec-RRLL-
cmk treated osteoblastic cultures (Fig. 4), we next 
asked whether the amount of activated caspase-3 
protein varied as a function of the inhibitor used.  
UMR106-01 cultures were treated for 12 h with a 
series of inhibitors as described in Figure 4.  Cell 
layers were then dissociated in hot SDS-8M urea 
solution containing an excess of DTT, and 
fractions were processed for Western blotting.  
The total cellular content of activated 19 kDa 
caspase-3 (45) was similar in mineralizing, un-
mineralized, and AEBSF–treated cultures (Fig. 
5D).  However, the caspase-3 content of dec-
RRLL-cmk treated cultures was greatly reduced 
(arrow, Fig. 5D).  By comparison, blots processed 
for control protein GAPDH gave similar band 
intensities for all conditions (Fig. 5E).   These 
results also suggest that activation of procaspase-3 
is decreased in dec-RRLL-cmk treated cultures 
compared with mineralizing, un-mineralized, and 
AEBSF–treated cultures.  Finally, the content of 
19 kDa caspase-3 was noticeably higher in 
cultures treated with 10 and 20 µM Z-DEVD-fmk 
or Z-DEVD-OPH than in controls (arrowheads, 
Fig. 5D).    
Treatment of UMR106-01 cells with AEBSF or 
with dec-RRLL-cmk alters the nuclear content of 
SKI-1 activated transcription factors.  To further 
test if SKI-1 is required for activation of SREBP 
and CREB/ATF family transcription factors which 
are imported into the nucleus where they control 
the expression of mineralization related genes, we 
asked whether AEBSF or dec-RRLL-cmk reduced 
the nuclear content of selected transcription 
factors.  Commonly, cells grown in 10% fetal 
bovine serum have been used as a control for 
caspase-3 activation since the serum cholesterol 
leads to feedback inhibition of SKI-1 activation of 
SREBPs.    As a result, Western blotting was used 
to identity the activating protease from the nuclear 
sizes of activated transcription factors 
To select which transcription factors to  
investigate, we searched for conserved 
transcription factor binding sites in the proximal 
promoter regions of the PHEX, DMP1, FN1, 
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COL11A1, COL1A2, and HMGCS1 genes using 
the NCBI ECR Browser program.  This analysis 
revealed that consensus SRE and CRE sequences 
exist in all of the six 5‘-proximal promoter regions 
(not shown). Additionally, OASIS was shown 
recently to be required for normal bone formation 
(25, 26) and CREB-H (CREB3L3) represents a 
CREB/ATF family member activated by SKI-1 
(33).  Expression of HMGCS1 is also regulated 
primarily by SREBP-1 and SREBP-2 (42, 43).  
Based on these findings, we focused our analyses 
on a mix of SRE and CRE binding factors:  
SREBP-1, CREB-H (CREB3L3), OASIS 
(CREB3L1), and SREBP-2. 
UMR106-01 cells were plated as usual in 10% 
fetal bovine serum (16) and at 64 h the media was 
exchanged again for serum free media containing 
either BGP alone (mineralizing conditions) or with 
AEBSF, dec-RRLL-cmk, or Z-DEVD-fmk.  Since 
AEBSF and dec-RRLL-cmk required only 12 h to 
reduce transcription of key mineralization genes 
(see Fig. 4), we also stopped these cultures 12 h 
after addition of inhibitors. Nuclear (Fig. 6) and 
cytoplasmic (Fig. 7) fractions were then 
immediately prepared for Western blotting.   
Nuclear OASIS consisted of a 58 kDa SKI-1 
activated form (OASIS panel, Fig. 6). This 
assignment is consistent  with the findings of 
Omori et al. (46).  The nuclear content of 58 kDa 
OASIS was lower in both the AEBSF and dec-
RRLL-cmk treated cultures (OASIS panel, Fig. 6).  
Parallel controls with cytoplasmic extracts from 
these same cultures were blotted against GADPH 
and show that the observed changes were not due 
to differences in sample loading (see Fig. 7).  
These results indicate that AEBSF and dec-RRLL-
cmk both reduce the nuclear content of SKI-1 
activated 58 kDa OASIS.   
In contrast to OASIS, the nuclear content of 
CREB-H did not change when AEBSF or dec-
RRLL-cmk was included.  Consistent with other 
work with this antibody (32), a 42 kDa band (SKI-
1 activated) and doublet immunoreactive bands 
containing 42 (SKI-1 activated) and 45 kDa 
(caspase-3 activated) forms were detected in +FBS 
cultures (CREB-H panel, Fig. 6).  Thus, CREB-H 
does not play a role in transcriptional changes 
brought about by AEBSF or dec-RRLL-cmk (Fig. 
4).   
The nuclear content of 68 kDa activated 
SREPB-2 was reproducibly decreased by both 
AEBSF and dec-RRLL-cmk (SREBP-2 panel, Fig. 
6).  By comparison, nuclei from +FBS treated 
cultures contained two closely spaced activated 
SREPB-2 forms at 68 kDa (SKI-1 cleavage) and at 
65 kDa (presumed to be cleaved by caspase-3).  
The nuclear content of 68 kDa SREBP-2 is 
reduced in cultures treated for 12 h with either 
AEBSF or dec-RRLL-cmk. 
SKI-1 activated SREBP-1 is also 68 kDa (20, 
21) as shown in the mineralized control (SREBP-1 
panel, Fig. 6).  This band is largely absent in non-
mineralizing conditions (No Phosphate, AEBSF, 
and dec-RRLL-cmk) (SREBP-1 panel, Fig. 6).   A 
separate 58 kDa form of SREBP-1 (produced by 
caspase-3) is present in +FBS cultures (20, 21).   
In order to confirm the assignment of caspase-
3 cleaved transcription factors in Figure 6, we 
isolated nuclear and cytoplasmic fractions from 
osteoblastic cultures treated with 10 and 20 µM Z-
DEVD-fmk  (Figs. 6 and 7). Our results show that 
the nuclear content of CREB-H was increased in 
cultures treated with 20 µM as compared with 
+BGP alone (CREB-H, panel, Fig. 6).  The 42 
kDa size of the activated nuclear CREB-H form 
whose content increased with 20 µM Z-DEVD-
fmk is consistent with its cleavage by SKI-1 
(CREB-H panel, Fig. 6).  
The effect of AEBSF and dec-RRLL-cmk inhibitors 
on cytoplasmic SKI-1 activated transcription 
factors.  Cytoplasmic transcription factor analysis 
provides a useful comparison with the nuclear 
profiles presented in Figure 6.  While carried out 
in triplicate, single representative patterns are 
presented in Figure 7. In contrast to the nuclear 
results, the content of cytoplasmic 58 kDa OASIS 
did not appear to correlate with the presence or 
absence of inhibitors (Fig. 7).  Cytoplasmic 
CREB-H consisted only of the SKI-1 activated 42 
kDa form (33) and its content also did not vary in 
the presence of inhibitors (CREB-H panel, Fig. 7).  
In support of this assignment, the 42 kDa form 
was absent from +FBS cultures.   
In contrast to results with nuclear fractions, 
analyses for cytoplasmic SREBP-2  revealed no 
detectable band under any culture condition 
(SREBP-2 panel, Fig. 7).  Also, Western blotting 
results for SREBP-1 yielded faint doublet bands at 
68 (SKI-1 activated) and 58 kDa (caspase-3 
activated) primarily in the FBS and Z-DEVD-fmk 
treated cultures (SREBP-1 panel, Fig. 7).  
However, the content of cytoplasmic SREBP-1 
forms did not change with inhibitors.  Finally, the 
content of control protein GAPDH in cytoplasmic 
extracts was constant among the different 
conditions (GADPH panel, Fig. 7) 
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Over-expression of SKI-1 activated SREBP-1 
increases mineralization in UMR106-01 cultures.  
To further test our hypothesis that osteoblastic 
mineralization is dependent upon  SKI-1 catalyzed 
activation of SREBP and CREB/ATF family 
transcription factors, we transiently over-
expressed SKI-1 activated transcription factors 
(SREBP-1a, SREBP-1c, SREBP-2, OASIS, and 
CREB-H) in UMR106-01 cells.    Plasmids were 
used which express active transcription factors  
retaining their nuclear import sequences and bZIP 
DNA binding domains but missing their C-
terminal membrane insertion sequences. All 
plasmids were compared over the same 
transfection dosage range which was optimized for 
SREBP-1a in initial titration studies.  Results are 
presented visually in Figure 8 after fluorescent 
staining for calcium mineral with Alizarin red S.       
Over-expression of SREBP-1a resulted in a 
significant increase in mineralized BMF 
complexes compared with the non-plasmid control 
or with cells transfected with OASIS, SREBP-2, 
or SREBP-1c (Fig. 8).  In a separate experiment, 
SREBP-1a transfected cells contained 1.32-fold 
more calcium in mineral deposits compared with 
the non-plasmid control (p<0.05).  Thus, over-
expression of SREBP-1a was able to increase both 
the number of biomineralization foci and the 
amount of calcium mineral deposited by UMR 
106-01 osteoblastic cells.  Also, CREB-H 
transfected UMR 106-01 cells exhibited an 
unusual morphological appearance.  In contrast to 
their usual dispersed appearance, BMFs in CREB-
H transfected cells were clumped together in 
discrete regions which resembled mineralization 
nodules seen in primary calvarial osteoblastic 
cultures (see Fig. 3).  
    
DISCUSSION 
We show here that mineralization, a property 
of differentiated osteoblastic cells, is blocked by 
covalent serine protease inhibitors AEBSF and 
dec-RRLL-cmk in two osteoblastic culture 
models. Since both inhibitors  inactivate SKI-1, an 
intracellular cis/medial-Golgi protease required for 
activation of SREBP and CREB/ATF family 
transcription factors, we examined the effect of 
these inhibitors on gene expression.   Short term 
(12 h) treatment of osteoblastic cultures with 
AEBSF decreased expression of 140 genes by 1.5- 
to 3.0-fold including Phex, Dmp1, COL1A1, 
COL1A2, COL11A1, and fibronectin.  A 
subsequent comparison of AEBSF with dec-
RRLL-cmk, a more specific SKI-1 inhibitor, on 
expression of a subset of these genes revealed two 
different outcomes.  Phex, Dmp1, COL11A1, and 
fibronectin were significantly reduced by both 
inhibitors.  COL1A2 and HMGCS1, a positive 
control for SKI-1 activity (42, 43), were also 
inhibited by AEBSF, but in contrast, expression 
was increased by dec-RRLL-cmk relative to 
mineralizing cultures.  AEBSF and dec-RRLL-
cmk also reduced the nuclear content of activated 
forms of OASIS, SREBP-1, and SREBP-2.  
Because caspase-3 is known to activate SREBP-1 
and SREBP-2 (20, 21), we also tested caspase-
3/capase-7 inhibitors; but Z-DEVD-fmk did not 
block osteoblastic mineralization. However, the 
activation and turnover of caspase-3 was 
differentially modified depending upon the 
inhibitor used, e.g., AEBSF, dec-RRLL-cmk, or Z-
DEVD-fmk.   In contrast to AEBSF, the actions of 
dec-RRLL-cmk represent the sum of its direct 
actions on SKI-1 and indirect actions on caspase-
3.  Specifically, dec-RRLL-cmk reduced 
intracellular caspase-3 activity by blocking the 
formation of activated 19 kDa caspase-3.  Finally, 
over-expression of the SKI-1 activated forms of 
SREBP-1a and of CREB-H in UMR106-01 
osteoblastic cells increased the number of 
mineralized foci and altered their local 
distribution, respectively.  These findings suggest 
that expression of key genes (Phex, Dmp1, 
COL11A1, and fibronectin) needed for 
mineralization of osteoblastic cultures in vitro and 
for bone formation in vivo are regulated by 
SREBP and CREB/ATF family transcription 
factors which require SKI-1 for their activation.   
Intracellular and extracellular roles for SKI-1 in 
osteoblastic mineralization.   Mineralization in 
UMR106-01 cultures is a temporally synchronized 
process and the first mineral crystals begin to 
form 12 h after addition of exogenous phosphate  
(13, 16, 17).  If phosphate is not added or if 
AEBSF is included, mineralization does not occur 
(16, 17).  AEBSF also blocks the fragmentation of 
phosphoproteins BSP and BAG-75 which are 
enriched within biomineralization foci, along with 
inhibiting activation of procollagen C proteinase 
enhancer protein. These results suggest that 105 
kDa SKI-1 may be responsible for extracellular 
proteolytic processing of secreted proteins within 
biomineralization foci.    
Since intracellular SKI-1 can also activate 
transmembrane transcription factor precursors, we 
carried out a whole genome array comparison of 
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mineralizing versus AEBSF treated cultures.  
Transcription of one-hundred forty genes was 
reduced by 1.5- to 3-fold including Phex, Dmp1, 
fibronectin, tenascin-N, tenascin-C, COL11A1, 
COL1A1, and COL1A2.  This result was then 
validated when six of these genes were retested 
with a more specific inhibitor of SKI-1, dec-
RRLL-cmk, using a qPCR approach.  
Furthermore, treatment of primary cultures of 
transgenic DMP1-GFP calvarial cells with both 
SKI-1 inhibitors not only blocked mineralization 
but also inhibited GFP expression driven by a 10 
kb DMP1 promoter.  These findings demonstrate 
for the first time that both a general and a specific 
inhibitor of SKI-1 protease are able to 
coordinately block transcription of this group of 
mineralization related genes.  Since inactivation or 
deletion of the type XI collagen, type I collagen, 
Dmp1, or Phex gene in vivo either causes a bone 
deficiency phenotype or abnormal skeletal 
development (2-5, 7, 8, 47, 48), we propose that 
their combined reduced transcription is the 
primary mechanism by which AEBSF and dec-
RRLL-cmk inhibit mineralization in osteoblastic 
cultures.   
An additional unexpected stimulatory effect of 
dec-RRLL-cmk on transcription of COL1A2 
suggests that type I collagen may not be required 
for initial mineral crystal nucleation and 
deposition within BMF in the UMR106-01 model.  
Rather, the blockage of procollagen C proteinase 
enhancer protein activation by AEBSF (16), which 
facilitates procollagen processing and fibril 
assembly, leads us to propose that type I collagen 
may function during subsequent propagation and 
growth of initial mineral crystals in this model.  
However, additional studies are needed to confirm 
that these transcriptional changes reflect 
differences in protein content.   
Consideration of the effects of AEBSF and 
dec-RRLL-cmk on gene expression in osteoblastic 
cells immediately raises questions about whether 
the promoters for fibronectin, DMP1, Phex, 
COL11A1, and COL1A2 are regulated by SKI-1 
activated transcription factors.  A review of the 
literature indicates that only the fibronectin and 
positive control HMG-CoA-Synthase promoters 
are known to be regulated by CREB and SREBP-2 
(42, 43, 49, 50).  However, ECR Browser searches 
of the proximal 5-6 kb promoters for the human, 
mouse, and rat fibronectin, Dmp1, Phex, 
COL11A1, HMG-CoA-Synthase, and COL1A2 
genes revealed conserved CRE and SRE 
consensus sequences in all six promoters (data not 
shown).  While these assignments do not ensure 
functionality, they are consistent with a common 
role for SKI-1 in regulating transcription of 
fibronectin, Dmp1, Phex, COL11A1, COL1A2, and 
HMG-CoA-Synthase.   
Analysis of nuclear transcription factor 
content and size supports a role for SKI-1 in 
mineralization.  The nuclear content of 58 kDa 
OASIS (CREB3L1) was decreased by AEBSF and 
dec-RRLL-cmk.  These results are consistent with 
the known role of SKI-1 in activating OASIS.  
Furthermore, changes in the nuclear OASIS 
content brought about by AEBSF and dec-RRLL-
cmk correlates well with changes both in the 
mineral content and with the expression of 
COL11A1, FN, Phex, and Dmp-1 in osteoblastic 
cultures.   
AEBSF and dec-RRLL-cmk each affected the 
nuclear contents of 68 kDa activated SREBP-1 
and SREBP-2 differently.  However, as expected, 
caspase-3 cleaved forms of SREBP-1 (58 kDa) 
and SREBP-2 (65 kDa) were enriched in +FBS 
cultures.  We presume that the cause for this 
change is serum cholesterol inhibition mediated by 
SCAP transport protein (41).   
The response of SREBP-1 and SREBP-2 to Z-
DEVD-fmk was also different. While the rationale 
for this finding is not clear, we suggest that 
SREBP-1 could be activated by another caspase 
not susceptible to this inhibitor or that turnover of 
SREBP-1 and SREBP-2 may follow distinct 
pathways.   
In summary, the nuclear contents of activated 
OASIS, SREBP-1, and SREBP-2 were all reduced 
in AEBSF and dec-RRLL-cmk treated cultures 
relative to mineralizing controls.  Since the 
proximal promoters for fibronectin, COL11A1, 
Phex, and Dmp-1 all contain SRE consensus 
sequences (data not shown), our results suggest 
that these inhibitors mediate their effects in 
osteoblastic cells by blocking activation and 
nuclear import of these SKI-1 activated 
transcription factors leading to their diminished 
nuclear contents and reduced transcription of 
fibronectin, COL11A1, Phex, and Dmp-1.      
Although fibronectin, COL11A1, Phex, and 
Dmp-1 responded uniformly to the presence of 
SKI-1 inhibitors, COL1A2 expression reacted 
oppositely and increased over controls in response 
to dec-RRLL-cmk.  We speculate that regulation 
of COL1A2 expression may be more complex and 
that our results may reflect the actions of non-SKI-
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1 regulated transcription factors.  However, it is 
interesting to note that despite an increase in 
COL1A2 expression, the overall effect of dec-
RRLL-cmk was to block mineralization in 
UMR106-01 cultures.      
Effects of inhibitors on caspase-3 activation 
and caspase-3 turnover.  SREBP-1, SREBP-2, and 
CREB transcription factors all appear to be subject 
to proteasomal degradation (53, 54).  Hirano et al. 
(53) showed that SREBP-1 is ubiquitinated and 
degraded in a manner consistent with the 
proteasome and that its 3 h half-life was increased 
when cells were treated with proteasome 
inhibitors.  Interestingly, when ubiquitination was 
blocked, a small increase in nuclear SREBP-1 and 
SREBP-2 content was observed along with an 
increase in expression of HMG-CoA Synthase.  
Three sites on SREBP-1 are important in terms of 
its phosphorylation (Thr426 and Ser430 and 
Ser434).  Interestingly, phosphorylation occurs 
after SREBP-1 binds to chromatin and is mediated 
by glycogen synthase kinase3-beta (55, 56) (see 
model, Fig. 9).   Ubiquitin ligase Fbw7 is then 
recruited to SREBP-1/promoter complexes 
following its phosphorylation and catalyzes 
ubiquitinylation of lysines with subsequent 
proteasomal degradation of the modified SREBP-
1.  Based on this requirement and recent 
identification of its nuclear localization sequence 
(57), we have proposed that GSK3-  can be 
imported into the nucleus (see model, Fig. 9).   
Because cytosolic caspase-3 can cleave 
adenomatous polyposis coli  protein and -catenin 
(58, 59), we speculate that a decrease in the 
intracellular content of activated caspase-3 could 
lead to an increase in cytosolic complexes of 
GSK3-  with APC and -catenin (see model, Fig. 
9).  In this way, less GSK3-  would then be 
imported into the nucleus where it would 
phosphorylate SREBP-1 (and possibly SREBP-2 
and OASIS)—leading to their ultimate 
proteasomal degradation.  Thus, when caspase-3 is 
inactivated by Z-DEVD-fmk or when activation of 
caspase-3 is inhibited by dec-RRLL-cmk, more 
GSK3-  is predicted to remain complexed with 
axin, catenin, and APC protein in the cytoplasm 
(60), unable to phosphorylate transcription factors, 
thus decreasing their turnover and transiently 
increasing their nuclear concentration.  In a similar 
way, caspase inhibitors Z-VAD-fmk and Z-
DEVD-fmk were shown to block apoptosis by 
suppressing NF-kappa B/p65 degradation, thereby 
increasing nuclear translocation, DNA binding and 
transcriptional activity (61).   
Direct Western blotting analyses demonstrated 
here that the level of activated 19 kDa caspase-3 
subunit was reduced in dec-RRLL-cmk treated 
cultures.  These findings are consistent the report 
by Park et al. (62) who showed that a serine 
protease was required to activate caspase-3 during 
apoptosis initiated by TNF-α.  These results 
suggest that SKI-1, a serine protease, can mediate 
directly or indirectly the activation of procaspase-3 
(see model, Fig. 9).   
Although many studies have linked activation 
of SREBP-1 and SREBP-2 with ER stress and 
apoptosis (24), recent work has shown that SREBP 
activation is also a characteristic of differentiated 
cellular pathways such as membrane biogenesis 
associated with phagocytosis (63), the secretion of 
insulin by pancreatic beta cells (64), and the 
transcription of the low density lipoprotein 
receptor by endothelial cells induced by shear 
stress (65).  Also SREBP-1c (ADD-1) (66) is a 
major positive regulator of fatty acid synthesis in 
developing adipogenic tissues.  Our results 
showing that SKI-1 inhibitors block mineralization 
and the coordinated transcription of key 
mineralization related genes support a requirement 
for SKI-1 in the differentiation of osteoblastic 
cells.  Prior evidence for a non-apoptotic role for 
caspase-3 in osteoblast differentiation was also 
presented by Mogi and Togari (67) and Miura et 
al. (68).   
        Our novel results demonstrate that a group of 
genes required for normal bone formation share a 
common transcriptional regulatory mechanism in 
mineralizing osteoblastic cells (see model, Fig. 9).  
Comparative Western blot analyses of the sizes 
and contents of transcription factors SREBP-1, 
SREBP-2, OASIS, and CREB-H in AEBSF or 
dec-RRLL-cmk treated cultures further support the 
role of SKI-1 in the activation of these 
transcription factors, and, implicitly, in the 
regulation of COL11A1, Phex, Dmp1, and 
fibronectin.  Careful analyses of the effects of 
these inhibitors also indicate a hierarchical 
relationship in which SKI-1 or another serine 
protease inhibited by dec-RRLL-cmk, but not by 
AEBSF, catalyzes the activation of caspase-3 in 
osteoblastic cells. Our results indicate that the 
differentiated phenotype of osteoblastic cells, and 
possibly osteocytes, depends upon the non-
apoptotic actions of SKI-1 to regulate the 
synthesis of proteins (and lipids for vesicles) 
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needed to assemble and mineralize the extracellular matrix of bone.   
 
REFERENCES 
1.  Lian JB, Stein GS.  1992.  Crit Rev Oral Biol Med. 3:269-305. 
2.  Ruchon AF, Tenenhouse HS, Marcinkiewicz M, Siegfried G, Aubin JE, DesGroseillers L, Crine 
P,     
     Boileau G.  2000. J Bone Miner Res 15:1440-1450. 
3. The HYP Consortium.  1995.  Nature Genet. 11:130-136. 
4.  Lorenz-Depiereux, B, Bastepe, M, Benet-Pages, A, Amyere, M, Wagenstaller, J, Muller-Barth, U,  
     Badenhoop, K, Kaiser, SM, Rittmaster, RS, Shlossberg, AH, Olivares, JL, Loris, C, Ramos, FJ,  
     Glorieux, F, Vikkula, M, Juppner, H, Strom, TM. 2006.  Nature Genet. 38: 1248-1250.  
5.  Feng, JQ, Ward, LM, Liu, S, Lu, Y, Xie, Y, Yuan, B, Yu, X, Rauch, F, Davis, SI, Zhang, S,    
     Rios, H, Drezner, MK, Quarles, LD, Bonewald, LF, White, KE.  2006.  Nature Genet. 38:  
     1310-1315.  
6.  Hansen U, Bruckner P.  2003.  J Biol Chem. 278:37352-37359.  
7.  Li Y, Lacerda DA, Warman ML, Beier DR, Yoshioka H, Ninomiya Y, Oxford JT, Morris NP,  
     Andrikopoulos, K, Ramirez F, et al.  1995.  Cell 80:423-430.  
8.  Richards, AJ, Yates, JRW, Williams, R, Payne, SJ, Pope, FM, Scott, JD, Snead, MP. 1996.   
     Hum. Molec. Genet. 5: 1339-1343.  
9.  Schneider GB, Zaharias R, Stanford C.  2001.  J Dent Res. 80:1540-1544. 
10.  Moursi AM, Damsky CH, Lull J, Zimmerman D, Doty SB, Aota S, Globus RK.  1996. J Cell 
Sci.     
      109:1369-1380. 
11.  Moursi AM, Globus RK, Damsky CH.  1997.  J Cell Sci.  110:2187-2196. 
12.  Stanford CM, Jacobson PA, Eanes ED, Lembke LA, Midura RJ.  1995. J. Biol Chem. 
270:9420- 
       9428. 
13. Wang, A, Martin, JA, Lembke, LA, and Midura, RJ. 2000. J. Biol. Chem. 275:11082-11091. 
14. Gorski JP, Wang A, Lovitch D, Law D, Powell K, Midura RJ.  2004. J Biol Chem. 279:25455. 
15. Midura RJ, Wang A, Lovitch D, Law D, Powell K, Gorski JP. 2004.  J Biol Chem. 279:25464.  
16. Huffman NT, Keightley JA, Chaoying C, Midura RJ, Lovitch D, Veno PA, Dallas 
SL, and Gorski JP.   
      2007.  J Biol Chem. 282:26002-26013. 
17.  Wang C, Wang Y, Huffman NT, Cui C, Yao X, Midura S, Midura RJ, Gorski JP.  2009. J Biol Chem  
       284:7100-713. 
18.  Gorski JP, Huffman NT, Cui C, Henderson E, Midura RJ, Seidah NG.   2009.  Tissues, Cells, and   
       Organs 189:25-32. 
19.  Seidah NG, Mayer G, Zaid A, Rousselet E, Nassoury N, Poirier S, Essalmani R, Prat A   
       2008.  Int J Biochem Cell Biol. 40:1111-1125.   
20.   Wang X, Pai JT, Wiedenfeld EA, Medina JC, Slaughter CA, Goldstein JL, Brown MS.  1995. 
J Biol     
        Chem. 270:18044-18050. 
21.  Wang X, Zelenski NG, Yang J, Sakai J, Brown MS, Goldstein JL.  1996.  EMBO J. 15:1012-
1020. 
22.  Higgins ME, Ioannou YA.  2001.  J Lipid Res. 42:1939-1946. 
23.  Guan G, Dai PH, Osborne TF, Kim JB, Shechter I.  1997.  J Biol Chem. 272:10295-102302. 
24.  Schröder M.  2008.  Cell Mol Life Sci. 65:862-894. 
25.  Murakami T, Kondo S, Ogata M, Kanemoto S, Saito A, Wanaka A, Imaizumi K.  2006.  J    
       Neurochem. 96:1090-100. 
26.  Murakami T, Saito A, Hino S, Kondo S, Kanemoto S, Chihara K, Sekiya H, Tsumagari K, Ochiai K,  
       Yoshinaga K, Saitoh M, Nishimura R, Yoneda T, Kou I, Furuichi T, Ikegawa S, Ikawa M, Okabe M,  
       Wanaka A, Imaizumi K.  2009.  Nature Cell Biol. 11:1205-1211. 
  13 
This is an author-produced, peer-reviewed version of this article.  The final, definitive version of this document can be found online at Journal 
of Biological Chemistry, published by American Society for Biochemistry and Molecular Biology. Copyright restrictions may apply.  DOI: 
10.1074/jbc.M110.151647 
 
27.  Chandhoke TK, Huang YF, Liu F, Gronowicz GA, Adams DJ, Harrison JR, Kream BE.  2008. 
Bone  
       43:101-109. 
28.  Schlombs K, Wagner T, Scheel J.  2003.  Proc Natl Acad Sci U S A. 100:14024-14029. 
29.  Patra D, Xing X, Davies S, Bryan J, Franz C, Hunziker EB, Sandell LJ.  2007.  J Cell Biol. 
179:687- 
       700. 
30.  Laemmli UK.  1970. Nature. 227:680-685. 
31.  Pullikotil P, Vincent M, Nichol ST, Seidah NG.  2004. J. Biol Chem. 279:17338-17347. 
32.  Pullikotil P, Benjannet S, Mayne J, Seidah NG.  2007.  Biol Chem.  282:27402-27413. 
33.  Zhang K, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, Back SH, Kaufman RJ.  2006.  Cell.  
      124:587-599.  
34.  Kalajzic I, Braut A, Guo D, Jiang X, Kronenberg MS, Mina M, Harris MA, Harris SE, Rowe 
DW.   
       2004.  Bone. 35:74-82. 
35.  Kalajzic I, Kalajzic Z, Kaliterna M, Gronowicz G, Clark SH, Lichtler AC, Rowe D.  2002.  J Bone    
       Miner Res. 17:15-25. 
36.  Kalajzic I, Staal A, Yang WP, Wu Y, Johnson SE, Feyen JH, Krueger W, Maye P, Yu F, Zhao Y,  
       Kuo L, Gupta RR, Achenie LE, Wang HW, Shin DG, Rowe DW.  2005. J Biol Chem. 280:24618- 
       24626. 
37.  Pasquato A, Pullikotil P, Asselin MC, Vacatello M, Paolillo L, Ghezzo F, Basso F, Di Bello C, Dettin      
       M, Seidah NG.  2006. J Biol Chem. 281:23471-23481. 
38.  Seidah NG, Mowla SJ, Hamelin J, Mamarbachi AM, Benjannet S, Touré BB, Basak A, Munzer JS,  
       Marcinkiewicz J, Zhong M, Barale JC, Lazure C, Murphy RA, Chrétien M, Marcinkiewicz M.  1999.  
       Proc Natl Acad Sci U S A. 96:1321-1326. 
39.  Elagoz, A, Benjannet, S, Mammarbassi, A, Wickham, L, and Seidah, NG. (2002) J. Biol. Chem. 277,  
       11265–11275.   
40.  Henrich S, Cameron A, Bourenkov GP, Kiefersauer R, Huber R, Lindberg I, Bode W, Than ME.      
       2003.  Nat Struct Biol. 10:520-526. 
41.  Nohturfft A, Yabe D, Goldstein JL, Brown MS, Espenshade PJ.  2000.  Cell  102:315-332. 
42.  Dooley KA, Bennett MK, Osborne TF.  (1999)  J. Biol Chem. 274:5285-5291.  
43.  Inoue J, Sato R, Maeda M.  (1998).  J Biochem. 123:1191-1198. 
44.  Chandler JM, Cohen GM, MacFarlane M.  1998. J Biol Chem. 273:10815-10818. 
45.  Liu X, Kim CN, Pohl J, Wang X.  1996.  J Biol Chem. 271:13371-13376. 
46.  Omori Y, Imai J, Suzuki Y, Watanabe S, Tanigami A, Sugano S.  2002.  Biochem Biophys Res     
       Commun. 293:470-477. 
47.  Dixon PH, Christie PT, Wooding C, Trump D, Grieff M, Holm I, Gertner JM, Schmidtke J, 
Shah B,  
       Shaw N, Smith C, Tau C, Schlessinger D, Whyte MP, Thakker RV.  1998. J Clin Endocrinol 
Metab.  
       83:3615-3623. 
48.  Pihlajaniemi T, Dickson LA, Pope FM, Korhonen VR, Nicholls A, Prockop DJ, Myers JC.  
1984. J  
       Biol Chem. 259:12941-12944. 
49.  Singh LP, Andy J, Anyamale V, Greene K, Alexander M, Crook ED.  2001.  Diabetes. 50:2355- 
       2362. 
50.  Michaelson JE, Ritzenthaler JD, Roman J.  2002.  Am J Physiol Lung Cell Mol Physiol. 282:L291- 
       301. 
51.  Starman, BJ, Eyre, D, Charbonneau, H, Harrylock, M, Weis, MA, Weiss, L, Graham, JM, Jr,  
       Byers, PH.  1989. J. Clin. Invest. 84: 1206-1214. 
52. Pastorino JG, Shulga N.  2008.  J. Biol Chem. 283:25638-25649. 
53. Hirano Y, Yoshida M, Shimizu M, Sato R.  2001.  J Biol Chem. 276:36431-36437. 
  14 
This is an author-produced, peer-reviewed version of this article.  The final, definitive version of this document can be found online at Journal 
of Biological Chemistry, published by American Society for Biochemistry and Molecular Biology. Copyright restrictions may apply.  DOI: 
10.1074/jbc.M110.151647 
 
54.  Costes S, Vandewalle B, Tourrel-Cuzin C, Broca C, Linck N, Bertrand G, Kerr-Conte J, 
Portha B,  
       Pattou F, Bockaert J, Dalle S.  2009.  Diabetes. 58:1105-1115.  
55.  Punga T, Bengoechea-Alonso MT, Ericsson J.  2006.  J. Biol. Chem. 281:25278-25286. 
56.  Bengoechea-Alonso MT, Ericsson J.  2009. J Biol Chem. 284:5885-5895. 
57.  Meares GP, Jope RS.  2007.  J.  Biol Chem. 282:16989-167001. 
58.  Webb SJ, Nicholson D, Bubb VJ, Wyllie AH.  1999.  FASEB J. 13:339-346. 
59.  Hunter I, McGregor D, Robins SP.  2001.  J. Bone Miner Res 16:466-477. 
60.  Farr, G. H., 3rd, Ferkey, D. M., Yost, C., Pierce, S. B., Weaver, C. and Kimelman, D.  (2000).  J. Cell  
       Biol. 148, 691-702. 
61.  Gupta S, Hastak K, Afaq F, Ahmad N, Mukhtar H.  2004.  Oncogene 23:2507-2522. 
62.  Park IC, Park MJ, Choe TB, Jang JJ, Hong SI, Lee SH.  2000.  Int J Oncol. 16:1243-1248. 
63.  Castoreno AB, Wang Y, Stockinger W, Jarzylo LA, Du H, Pagnon JC, Shieh EC, Nohturfft A.  
2005.   
       Proc Natl Acad Sci U S A. 102:13129-13134. 
64.  Amemiya-Kudo M, Oka J, Ide T, Matsuzaka T, Sone H, Yoshikawa T, Yahagi N, Ishibashi S, 
Osuga     
       J, Yamada N, Murase T, Shimano H.  2005. Biol Chem. 280:34577-34589. 
65.  Liu Y, Chen BP, Lu M, Zhu Y, Stemerman MB, Chien S, Shyy JY.  2002. Arterioscler Thromb 
Vasc  
       Biol. 22:76-81. 
66.  Gondret F, Ferré P, Dugail I.  2001.  J Lipid Res. 42:106-113. 
67.  Mogi M, Togari A.  2003. J. Biol Chem.  278:47477-47482. 
68.  Miura M, Chen XD, Allen MR, Bi Y, Gronthos S, Seo BM, Lakhani S, Flavell RA, Feng XH, Robey  
       PG, Young M, Shi S.  2004.  J Clin Invest. 114:1704-1713. 
 
 
 
 
ACKNOWLEGEMENTS 
The authors wish to acknowledge the valuable technical assistance provided by Ms. Ellen Henderson and 
Pat Veno; Mr. Adnan Cheema provided important graphical support.  JPG wishes to also thank the Bone 
Biology Group at UMKC for their long term support on this project and Dr. Tim Osborne, U. C. Irvine, 
for his generous assistance in analysis of SKI-1 activated transcription factors.  JPG also wishes to thank 
Dr. Kezhong Zhang, Wayne State University, for providing anti-CREB-H antiserum.  Supported by grant 
funds to JPG (NIH NIAMS R01-052775, UMKC Center of Excellence for Mineralized Tissues, and the 
University of Missouri Research Board); NGS was supported by a Canadian CIHR TEAM grant number 
CTP 82946. Funding from NIH NCRR P20RR016454 supported research infrastructure at Boise State 
University. 
6
ABBREVIATIONS 
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proprotein convertase; AEBSF,  4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride; SREBP, sterol 
regulatory element-binding transcription factor; SCAP, SREBF cleavage activating protein; BMF, 
biomineralization foci; FBS, fetal bovine serum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
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Leu-Leu-chloromethyl ketone; FGF23, fibroblast growth factor 23; and, ICER, inducible cyclic AMP 
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FIGURE LEGENDS 
Figure 1.  Activated 105 kDa SKI-1 is localized to extracellular calcified biomineralization foci in 
osteoblastic cultures. 
A, Comparative Western blotting of laser micro dissected biomineralization foci with total cell 
layer extracts from osteoblastic cultures with anti-C-terminal SKI-1 antibodies.  UMR106-01 
osteoblastic cells were grown on glass slides, allowed to mineralize as described (13) and resultant 
mineralized biomineralization foci were isolated by laser micro dissection after staining with Alizarin red 
S dye; and isolated BMF and total cell layer fractions were then extracted and subjected to Western 
blotting as described previously (16).  Six micrograms of protein was applied to each lane.  No 
immunoreactive bands were detected in extraction buffer alone controls (Buffer, Fig. 1A). Numbers of 
left margin refer to estimated molecular weights of immunoreactive bands.  KEY:  BMF, 
biomineralization foci isolated by laser micro dissection; CL-Min, total cell layer from mineralized 
culture; CL-UnMin, total cell layer from non-mineralized culture; Buffer, control for extraction buffer.   
B, Comparative Western blotting of cell layer extracts and media fractions from mineralized, 
AEBSF-inhibited, and non-mineralized osteoblastic cultures.  Media was removed and the residual 
cell layer fraction was then extracted sequentially with 0.05 M EDTA and with 8M urea/0.5% CHAPS as 
described by Huffman et al. (16).  Equivalent amounts of each fraction (urea/CHAPS extract, EDTA 
extract, and media) were subjected to Western blotting with anti-C-terminal SKI-1 antibodies using 
chemiluminescent detection.  Numbers of left margin refer to estimated molecular weights of 
immunoreactive bands.  KEY:  BGP, with 6.5 mM -glycerolphosphate; and, AEBSF, with 100 µM 4-
(2-aminoethyl) benzene sulfonyl fluoride hydrochloride.  
 
Figure 2.  SKI-1 specific inhibitor, dec-RRLL-cmk, like AEBSF, specifically inhibits mineralization 
in UMR106-01 osteoblastic cultures.   
Error bars refer to standard deviations; probabilities were determined by a one-way ANOVA with a 
Student-Newman-Keuls multiple comparison test.   
A, Titration of dec-RRLL-cmk demonstrates its capacity to completely block mineralization 
without affecting cell viability.  Osteoblastic cells were grown as usual and treated for 24 h under 
mineralizing conditions (see METHODS) with different concentrations of inhibitor.  Mineralization was 
assayed with a colorimetric calcium assay by reference to a standard curve; cell viability was determined 
using the MTT assay.   
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B, Side-by-side comparison reveals dec-RRLL-cmk and AEBSF both completely block 
mineralization in culture. KEY:  +BGP, plus -glycerolphosphate; -BGP, minus -glycerolphosphate; 
dec-RRLL-cmk, 40 µg/ml inhibitor; and, AEBSF, 100 µM inhibitor.  
C, Furin peptide inhibitor dec-RVKR-cmk is without effect on mineralization.  KEY:  +BGP, plus 
-glycerolphosphate; -BGP, minus -glycerolphosphate; dec-RVKR-cmk, range of concentrations from 
8 to 75 micromolar; and, DMSO, high and low represent solvent controls.  
 
Figure 3.  SKI-1 inhibitor dec-RRLL-cmk also blocks mineralization of primary mouse calvarial 
osteoblastic cells.  
Primary mouse calvarial cells from transgenic DMP1 GFP mice (34) were harvested by a conventional 
sequential collagenase digestion protocol and plated as noted in METHODS.  The media was changed at 
three day intervals starting on day 3 after plating.  Some cultures were treated with SKI-1 inhibitors.  
Scale bars=375 microns  
A, Control calvarial cells produced mineralized nodules on day 12 after plating.  Mineralized 
nodules were detected by fluorescence microscopy after staining the culture with 10 µg/ml Alizarin red S 
dye.  Green fluorescent signal represents GFP protein expressed under control of the 10 kb Dmp1 
promoter.  Yellow represents areas of overlap of mineral (red) and GFP signals. Arrows demark 
mineralized areas which also express GFP protein.     
B,  Dec-RRLL-cmk blocks the mineralization of primary calvarial cells as well as expression of 
GFP protein.  Cells were treated continuously from day 3 until day 12 with 8 µM dec-RRLL-cmk 
inhibitor and then the cultures were imaged by fluorescence microscopy as in A.   
C, AEBSF inhibits the mineralization of primary calvarial cells as well as expression of GFP 
protein.  Cells were treated continuously from day 3 until day 12 with 10 µM AEBSF inhibitor and then 
the cultures were imaged by fluorescence microscopy as in A.  
 
Figure 4.  Dec-RRLL-cmk and AEBSF block expression by UMR106-01 osteoblastic cells of key 
genes required for mineralization and for normal bone formation.   
Total RNA was isolated from replicate cultures (n=6/condition) treated for 12 h with β-glycerolphosphate 
with or without inhibitors and converted into cDNA with reverse transcriptase (see METHODS).  
Quantitative PCR was carried out using primer sets for individual genes and the relative expression for 
each gene was plotted as a percentage of that expressed by mineralized control cultures.  Error bars refer 
to standard deviations and probabilities were calculated using a one-way ANOVA test.  KEY:  +BGP, 
control cultures treated with mineralizing conditions (6.5 mM β-glycerolphosphate); +AEBSF+BGP, 
cultures treated for 12 h with 100 µM AEBSF under mineralizing conditions; +Dec-RRLL-cmk+BGP; 
cultures treated for 12 h with 40 µM dec-RRLL-cmk under mineralizing conditions.   
 
A-F, Quantitative PCR results for Dmp1, COL11A1, fibronectin, Phex, COL1A2, and HMGCS1 genes.   
 
Figure 5.  Dec-RRLL-fmk partially blocks activation of caspase-3 although caspase-3 inhibitors do 
not inhibit osteoblast-mediated mineralization.  
UMR106-01 cultures were treated with β-glycerolphosphate with or without inhibitors and then cell layer 
fractions were assayed for soluble caspase-3 activity, mineral calcium content, and caspase-3 protein 
content by Western blotting as described in EXPERIMENTAL PROCEDURES.  The direct effects of 
inhibitors on recombinant caspase-3 was analyzed separately.  Error bars represent standard deviations 
and probabilities were tested with a one-way ANOVA test using a Student-Newman-Keuls multiple 
comparison test.   
KEY:  Mineralized,  cells treated with β-glycerolphosphate; Un-mineralized, no β-glycerolphosphate; 
+AEBSF, cells treated with 100 µM inhibitor and β-glycerolphosphate; +Dec-RRLL-cmk, cells treated 
with 40-50 µM inhibitor and β-glycerolphosphate; + 10 Z-DEVD-fmk, cells treated with 10 µM inhibitor 
and β-glycerolphosphate; + 20 Z-DEVD-fmk, cells treated with 20 µM inhibitor and β-
glycerolphosphate; + 10 Z-DEVD-OPH, cells treated with 10 µM inhibitor and β-glycerolphosphate;  + 
20 Z-DEVD-OPH, cells treated with 20 µM inhibitor and β-glycerolphosphate.   All results are 
representative of at least duplicate experiments.                    
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A, Treatment of UMR106-01 osteoblastic cultures with Z-DVED-fmk does not block 
mineralization.  The average amount of calcium deposited in biomineralization foci was then determined 
colorimetrically (n=6).   
B, Z-DVED-fmk and Dec-RRLL-cmk lead to significant reductions in intracellular caspase-3 
activity.  Soluble intracellular caspase-3 activity was extrapolated from kinetic reaction plots; the 
averaged data is plotted as Arbitrary Fluorescence Units/h (n=6). 
C, Dec-RRLL-cmk does not directly inactivate recombinant caspase-3.   Activity was extrapolated 
from kinetic reaction plots and is plotted as the average nmoles AMC released/h/ng protein (n=6).  
D, Western blot analysis for precursor and activated caspase-3 forms.  The amount of procaspase-3 
32 kDa and of intracellular activated 19 kDa caspase-3 subunit varies depending upon the protease 
inhibitor treatment.  The total cell layer of treated UMR106-01 cultures was extracted with hot SDS/urea 
sample buffer and subjected to Western blotting with anti-caspase-3 antibodies.  The pattern is 
representative of triplicate experiments.  Arrow denotes decreased 19 kDa band in dec-RRLL-cmk 
treated cells; arrowheads demark increased 19 kDa band content in cells which were treated with 
caspase-3 Z-DEVD-fmk or Z-DEVD-OPH inhibitor.  
E,  Western blot for intracellular GAPDH control.  The cell layers in triplicate wells were extracted 
with hot SDS/urea sample buffer and subjected to Western blotting with anti-GADPH antibodies.   
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Figure 6.  AEBSF, dec-RRLL-cmk, and Z-DEVD-fmk inhibitors alter the nuclear content of SKI-1 
activated transcription factor(s).   
Cultures were treated for 12 h under mineralizing conditions with different protease inhibitors and the 
nuclear fraction was then isolated.  All culture conditions were carried out in triplicate and Western 
blotting results for OASIS, CREB-H, SREBP-1, and SREBP-2 depicted are representative of these 
replicates.  Cytoplasmic fractions were also isolated from these same cultures and Western blots for 
control protein GAPDH are shown in Figure 7.  All lanes shown for each different transcription factor 
were imaged similarly and at the same time. KEY:  Mineralizing, cells treated with mineralizing 
conditions (6.5 mM  β-glycerolphosphate); No Phosphate, no -glycerolphosphate added; +AEBSF, 
cells treated with 100 µM inhibitor; +Dec-RRLL-cmk, cells treated with 40 µM dec-RRLL-cmk; 10 Z-
DEVD-fmk, cells treated with 10 µM inhibitor; 20 Z-DEVD-fmk, cells treated with 20 µM inhibitor.  
 
OASIS panel, nuclear fractions subjected to Western blotting for OASIS.   
CREB-H panel, nuclear fractions subjected to Western blotting for CREB-H.   
SREBP-1 panel, nuclear fractions subjected to Western blotting for SREBP-1.   
SREBP-2 panel, nuclear fractions subjected to Western blotting for SREBP-2.  
 
Figure 7.  Cytoplasmic contents of selected SKI-1 activated transcription factors.   
Cultures were treated for 12 h under mineralizing conditions with different protease inhibitors and then 
the cytoplasmic fraction was isolated from each using a commercial kit.  All culture conditions were 
carried out in triplicate and results shown are representative of these replicates and GAPDH Western blots 
were used to control for intra-culture variations.  Nuclear fractions were also isolated from these same 
cultures.  All lanes shown on each panel below was imaged similarly and at the same time.  
KEY:  Mineralizing,  cells treated with 6.5 mM  -glycerolphosphate; No Phosphate, no -
glycerolphosphate added; +AEBSF, cells treated with 100 µM inhibitor; +Dec-RRLL-cmk, cells treated 
with 40 µM dec-RRLL-cmk; 10 Z-DEVD-fmk, cells treated with 10 µM inhibitor; 20 Z-DEVD-fmk, 
cells treated with 20 µM inhibitor.  
 
OASIS panel, cytoplasmic fractions subjected to Western blotting for OASIS.   
CREB-H panel, cytoplasmic fractions subjected to Western blotting for CREB-H.   
SREBP-1 panel, cytoplasmic fractions subjected to Western blotting for SREBP-1.   
SREBP-2 panel, cytoplasmic fractions subjected to Western blotting for SREBP-2.   
GAPDH panel, cytoplasmic fractions subjected to Western blotting for GAPDH.  
 
Fig. 8.  Over-expression of activated forms of SREBP-1a and CREB-H in UMR106-01 cells 
increases the number and clustering of mineralized biomineralization foci, respectively.   
Forty hours after plating, cells were transiently transfected with plasmid in the presence of Metafectamine 
Pro and grown under standard mineralizing conditions (see METHODS).  At 88 h, cultures were fixed 
with 70% ethanol, stained with Alizarin red S dye, and photographed using a fluorescence microscope.  
Mineralized BMF appear as white dots or clusters (arrows) under these conditions.   Over-expression with 
activated OASIS, SREBP-1c, and SREBP-2 was without effect and indistinguishable from non-plasmid 
control cultures.  Calcium assays revealed that SREBP-1c transfected cells deposited 1.32-fold more 
hydroxyapatite than non-plasmid control cells (p<0.05).  Scale bar=500 µm.    
 
Figure 9.  Proposed intracellular mechanism of AEBSF, Dec-RRLL-cmk, and Z-DEVD-fmk effects 
on gene expression by osteoblastic cells.    
Steps depicted in bold type are those suggested from experimental data presented here.  Other parts of the 
model are derived from a variety of literature sources referenced in the Discussion section.   
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TABLE 1 
The effect of Inhibitors on Total Cellular SKI-1 Peptidase Activity  
 
Replicate cultures (n=6) were stopped 8 h after the addition BGP and SKI-1 assays carried out on total 
cell lysates as described in EXPERIMENTAL PROCEDURES.  Data analyzed using a 1-way ANOVA 
with a Student-Newman-Keuls multiple comparison test.  Representative of duplicate experiments. 
  
 
TABLE 2 
AEBSF blocks transcription of a number of key mineralization 
related genes in whole array study with UMR106-01 cells 
Fold Change Gene 
symbol 
Description  
-1.58 Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 
-1.59 Senp7  SUMO1/sentrin specific protease 7 
 
-1.64 Adamtsl1 
 
AdamTS1 like protease 
-1.66 Phex  Phosphate regulating gene with homologies to  
endopeptidases on the X chromosome 
-1.67 Casp4 Caspase 4 
-1.77 Enpp3 Alkaline phosphodiesterase 
-1.85 Fbn2 Fibrillin 2 
-1.90 Enpp2 Ectonucleotide pyrophosphatase/ 
phosphodiesterase 2 
-1.90 Tnc Tenascin C 
-1.91 pColA1 (I) Procollagen, type I, alpha 1 chain  
-1.94 Mitf Microphthalmia-associated transcription factor 
-1.97 Atp1a2 ATPase, Na+K+ transporting, alpha 2 
-1.97 Tnn Tenascin N 
-1.98 Fn Fibronectin 1 
-2.10 Scn1a Sodium channel voltage-gated, type 1 alpha 
-2.13 pColA1(XI)   Procollagen, type XI, alpha 1 chain  
-2.18 pColA2(I) Procollagen, type I, alpha 2 chain  
-2.28 Acss2 Acyl CoA synthetase short chain family member 2 
-2.37 Serpini1 Serine (cysteine) peptidase inhibitor 
-2.50 DMP-1 Dentin matrix protein-1 
-2.55 pColA2(I) Procollagen, type I, alpha 2 chain  
-2.99 Matn3 Matrilin 3 
Culture Condition  Peptidase Activity +/- STD 
(Arbitrary fluorescence units/ h / 
culture well) x 1000 
Percent of 
Control 
Statistical  
Significance  
Mineralizing Control (+BGP) 1616 +/- 58.3 100% +/- 3.6  
+100 µM AEBSF +BGP 1161 +/- 145.0 71.8% +/- 12.5 p<0.05  
+50 µM Dec-RRLL-cmk +BGP 986 +/- 125.6 61.0% +/- 12.7  p<0.05    
+20 µM DEVD-OPH +BGP 1727 +/- 67.9 106.8% +/- 3.9  
+75 µM Dec-RVKR-cmk +BGP 1807 +/- 119.0 111.8% +/- 6.6  
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FIGURE 1 
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FIGURE 2 
 
 
 
 
 
 
 
FIGURE 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  22 
This is an author-produced, peer-reviewed version of this article.  The final, definitive version of this document can be found online at Journal 
of Biological Chemistry, published by American Society for Biochemistry and Molecular Biology. Copyright restrictions may apply.  DOI: 
10.1074/jbc.M110.151647 
 
 
 
FIGURE 4 
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FIGURE 5 
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FIGURE 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 
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FIGURE 8 
 
 
 
 
 
 
 
FIGURE 9 
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